CoChat

Expression of bcl-xL can confer a multidrug resistance phenotype

Minn, AJ, Rudin, CM, Boise, LH, Thompson, CB · 1995 · Blood

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Abstract

It has been suggested that genes that regulate apoptotic cell death may play an important role in determining the sensitivity of tumor cells to chemotherapy. We have recently cloned a member of the bcl-2 family, bcl- x. To test whether bcl-XL expression affects the sensitivity of tumor cells to chemotherapy, we have created stable cell lines overexpressing bcl-XL and have tested these cells for resistance to cell death induced by metabolic inhibitors and chemotherapeutic agents. Bcl-XL expression dramatically reduces the cytotoxicity of bleomycin, cisplatin, etoposide, vincristine, hygromycin B, and mycophenolic acid for up to 4 days in culture. Bcl-XL does not prevent cells from undergoing cell cycle arrest in response to these drugs, but rather prevents treated cells from undergoing apoptosis. Cell-cycle analysis on cells treated with the chemotherapeutic agents bleomycin, cisplatin, etoposide, and vincristine, show that the drugs cause growth arrest in different positions within the cell cycle. Bcl-XL expressing cells treated with chemotherapeutic drugs retain their proliferative ability after the drugs are removed. Interestingly, vincristine-treated cells expressing bcl-XL become polyploid after drug removal. These data show that bcl-XL protects cells from a wide variety of apoptotic stimuli, acts in multiple positions within the cell cycle, and confers a multidrug resistance phenotype. The ability of bcl-XL to prevent apoptotic cell death in response to chemotherapy-induced DNA damage and cell-cycle arrest may contribute to the accumulation of chromosomal aberrations within tumors. The expression of bcl-XL in tumor cells is likely to be an important indicator of chemotherapeutic efficacy.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood.v86.5.1903.bloodjournal8651903

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 31 references

Cited by

See all 415

Metadata

Authors
Minn, A., Rudin, C., Boise, L., & Thompson, C.
Affiliations
Gwen Knapp Center for Lupus and Immunology Research, Department of Medicine, University of Chicago, IL 60637–5420, USA.
Venue
Blood
Published
1995-09-01
Volume
86
Issue
5
Pages
1903-1910
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W161930446
Cited by
415
References
32
Citations by year
2026: 2 · 2025: 4 · 2024: 8 · 2023: 6 · 2022: 10 · 2021: 9 · 2020: 10 · 2019: 8 · 2018: 3 · 2017: 7 · 2016: 14 · 2015: 9 · 2014: 12 · 2013: 14 · 2012: 9
FWCI
9.54
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute of Allergy and Infectious Diseases (P01-AI 35294, P01AI035294)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
Bcl-xL, multidrug resistance, apoptosis, chemoresistance, Bcl-2 family proteins, cell cycle arrest, bleomycin, cisplatin, etoposide, vincristine, hygromycin B, mycophenolic acid, polyploidy, chromosomal abnormalities, tumor cell proliferation, chemotherapy efficacy
MeSH terms
Animals, Antimetabolites, Antineoplastic, Antineoplastic Agents, Cell Cycle, Cell Survival, Dose-Response Relationship, Drug, Multigene Family, Humans, Kinetics, Proto-Oncogene Proteins, Recombinant Proteins, Time Factors, Transfection, Tumor Cells, Cultured, Gene Expression, Apoptosis, Drug Resistance, Multiple, Proto-Oncogene Proteins c-bcl-2, bcl-X Protein, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Expression of bcl-xL can confer a multidrug resistance phenotype. https://app.cochat.ai/papers/10.1182/blood.v86.5.1903.bloodjournal8651903
The paper
Minn, A., Rudin, C., Boise, L., & Thompson, C. (1995). Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. https://doi.org/10.1182/blood.v86.5.1903.bloodjournal8651903

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.